Investigation of serotonin-related genes in antidepressant response

Molecular Psychiatry

Volumn 9, Issue 9, 2004, Pages 879-889

  Peters, E J ^a   Slager, S L ^b   McGrath, P J ^c   Knowles, J A ^c   Hamilton, Steven P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mayo Clinic   (United States)

^c New York State Psychiatric Institute ^*  (United States)

Author keywords

Antidepressant; Association; Linkage disequilibrium; Pharmacogenetic; SNP, haplotype

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN;

ADULT; ALLELE; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HAPLOTYPE; HTR1A GENE; HTR2C GENE; HUMAN; MAJOR DEPRESSION; MALE; MAOA GENE; PRIORITY JOURNAL; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A4 GENE; TPH1 GENE; TPH2 GENE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DRUG RESISTANCE; FLUOXETINE; GENE FREQUENCY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MONOAMINE OXIDASE; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE;

EID: 4644303054     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001502     Document Type: Article

References (61)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105.
3. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62(Suppl 16): 10-17.
4. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-128.
5. Veenstra-VanderWeele J, Anderson GM, Cook Jr EH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410: 165-181.
6. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255-275.
7. Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531.
8. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
9. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323-330.
10. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2003 Epub: DOI: 10.1007/s00213-003-1562-3.
11. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 2000; 11: 215-219.
12. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
13. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
14. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467-489.
15. Sargent P, Williamson DJ, Pearson G, Odontiadis J, Cowen PJ. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity. Psychopharmacology (Berl) 1997; 132: 296-302.
16. Zanardi R, Artigas F, Moresco R, Colombo C, Messa C, Gobbo C et al. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 2001; 21: 53-58.
17. Kim SW, Park SY, Hwang O. Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Mol Pharmacol 2002; 61: 778-785.
18. Stokes AH, Xu Y, Daunais JA, Tamir H, Gershon MD, Butkerait P et al. p-ethynylphenylalanine: a potent inhibitor of tryptophan hydroxylase. J Neurochem 2000; 74: 2067-2073.
19. Zimmer L, Luxen A, Giacomelli F, Pujol JF. Short- and long-term effects of p-ethynylphenylalanine on brain serotonin levels. Neurochem Res 2002; 27: 269-275.
20. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1279-1283.
21. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002; 5: 27-35.
22. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
23. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375-380.
24. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J et al. Predictors of relapse during fluoxetine continuation of or maintenance treatment of major depression. J Clin Psychiatry 2000; 61: 518-524.
25. First M, Spitzer R, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P), Version 2.0. 1995.
26. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998: 55: 334-343.
27. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782-786.
28. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry 1999; 156: 829-836.
29. Iyengar S, Seaman M, Deinard AS, Rosenbaum HC, Sirugo G, Castiglione CM et al. Analyses of cross species polymerase chain reaction products to infer the ancestral state of human polymorphisms. DNA Sequence 1998; 8: 317-327.
30. Chen X, Levine L, Kwok PY. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 1999; 9: 492-498.
31. Hamilton SP, Slager SL, Heiman GA, Deng Z, Haghighi F, Klein DF et al. Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biol Psychiatry 2002; 51: 591-601.
32. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S. (eds). Bioinformatics Methods and Protocols. Human Press: Totowa, NJ, 2000; 365-386.
33. Melke J, Landen M, Baghei F, Rosmond R, Holm G, Bjorntorp P et al. Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. Am J Med Genet 2001; 105: 458-463.
34. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
35. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002; 53: 146-152.
36. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59(Part 1): 97-105.
37. Schneider S, Roessli D, Excoffier L. Arlequin: A Software for Population Genetics Data Analysis, Ver 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva. Geneva, Switz, 2000.
38. Ke X, Cardon LR. Efficient selective screening of haplotype tag SNPs. Bioinformatics 2003; 19: 287-288.
39. Abecasis GR, Cookson WO. GOLD-graphical overview of linkage disequilibrium. Bioinformatics 2000; 16: 182-183.
40. Bacanu SA, Devlin B, Roeder K. The power of genomic control. Am J Hum Genet 2000; 66: 1933-1944.
41. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233-237.
42. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.
43. Devlin B, Roeder K, Wasserman L. Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 2001; 60: 155-166.
44. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-228.
45. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
46. Gelernter J, Kranzler H, Coccaro EF, Siever LJ, New AS. Serotonin transporter protein gene polymorphism and personality measures in African American and European American subjects. Am J Psychiatry 1998; 155: 1332-1338.
47. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389.
48. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997; 101: 243-246.
49. Gabriel SB, Schaffner Sf, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
50. Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29: 223-228.
51. Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, Riley J et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 2000; 67: 383-394.
52. Zhang K, Calabrese P, Nordborg M, Sun F. Haplotype block structure and its applications to association studies: power and study designs. Am J Hum Genet 2002; 71: 1386-1394.
53. Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995; 20: 265-270.
54. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-732.
55. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737.
56. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-129.
57. Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol 2001; 20: 4-16.
58. Devlin B, Roeder K, Bacanu SA. Unbiased methods for population-based association studies. Genet Epidemiol 2001; 21: 273-284.
59. Hacia JG, Fan JB, Ryder O, Jin L, Edgemon K, Ghandour G et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet 1999; 22: 164-167.
60. Dupont WD, Plummer J. Power and sample size calculations *1: A review and computer program. Controlled Clin Trials 1990; 11: 116-128.
61. Weiss KM, Clark AG. Linkage disequilibrium and the mapping of complex human traits. Trends Genet 2002; 18: 19-24.